Mark Day

Biography

Mark Day, Ph.D., is the president and chief executive officer at Bioasis Technologies, Inc. Dr. Day most recently served as head, CNS virtual discovery, at Purdue Pharma. Prior to joining Purdue Pharma, he served as executive director, head of external research and scouting, at Alexion Pharmaceuticals, Inc. Dr. Day also serves as adjunct associate professor at Yale University. He is widely recognized for his expertise and success in the recognition, evaluation and development of pipeline acquisition and collaboration targets across several therapeutic areas. Demonstrating corporate leadership, Dr. Day has developed business plans for Alexion Pharmaceuticals, Purdue Pharma, Wyeth and Bristol-Myers Squibb in multiple functional areas ranging from the development of external research discovery engines and global scouting strategies to the creation of internal venture/investment funds. He was instrumental in the acquisition of iPierian for BMS and he has developed strategies that can shorten evaluation periods by several months, leading to early decisions regarding the advancement or early termination of the evaluative processes. Dr. Day has presented his evaluations and formal recommendations at the highest corporate levels. He has also participated in the resulting deal negotiations, leading to several high-profile acquisitions and collaborations. He has more than 60 peer-reviewed manuscripts, including first authorships in Nature, Science, Proceedings of the Royal Society, etc. Dr. Day earned his bachelor of science degree in biological psychology and his doctor of philosophy degree in neuroscience from Cardiff University. Dr. Day’s postdoc in systems level neuroscience is from The University of Edinburgh.

Research Interest

Biological Psychology, Neuroscience and Pharmaceutical Science.